Selanksafety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for Selank as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. Selank is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

Selank has a substantial Russian clinical-use safety dataset accumulated through anxiolytic registration and post-marketing surveillance. The adverse-event profile reported in Russian clinical experience is favourable: mild and transient adverse effects predominate, with nasal irritation (mild stinging, occasional runny nose) being the most common; occasional mild fatigue; rare reports of transient gastrointestinal upset. No clinically significant changes in routine haematology, biochemistry, or vital signs have been documented. The principal safety feature distinguishing Selank from benzodiazepine comparators is the absence of sedation, cognitive impairment, tolerance, dependence, and withdrawal syndrome. Russian clinical practice has used chronic Selank dosing (months) without surfacing the dependence and withdrawal phenomena that limit chronic benzodiazepine use, and without the cognitive-impairment and psychomotor-slowing effects that complicate benzodiazepine pharmacology. This favourable comparison is the principal mechanistic argument for Selank over benzodiazepines in chronic anxiety management. Western pre-clinical safety data are limited but consistent with the Russian clinical experience. Acute and sub-chronic rodent toxicology studies have not identified dose-limiting organ-specific toxicity at doses materially above the human clinical equivalent. The intranasal route limits systemic exposure to a fraction of central exposure, further reducing off-target peripheral safety concerns. Theoretical safety considerations centre on the immunomodulatory ancestry of the tuftsin sequence. Chronic Selank dosing could theoretically affect T-cell function, NK cell activity, and inflammatory cytokine production in clinically meaningful ways, particularly in immunocompromised subjects or in subjects with autoimmune disease. The Russian clinical experience has not surfaced significant signals in these domains, but the chronic-dosing record is not equivalent to a formal Western Phase III/IV regulatory dataset. No serious acute adverse events have been documented at research-protocol doses. The acute safety profile is favourable; the chronic-dosing record from Russian clinical use is the principal long-term safety dataset.

UK regulatory status

Selank is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any Western jurisdiction. It is a registered prescription anxiolytic medicine in Russia; this registration does not confer UK regulatory status. Selank is not a controlled substance under the Misuse of Drugs Act 1971. Possession of research-grade material for bona fide in-vitro and animal research is generally unrestricted in the UK. Supply or administration of Selank to humans outside an authorised UK clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence — the Russian registration does not authorise UK supply or use. Selank is not currently on the WADA Prohibited List. Its anxiolytic and modest nootropic mechanisms do not currently fall within any WADA category, though athletes should verify the current annual Prohibited List. For animal research under ASPA, Selank work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit. As with Semax, UK individuals occasionally obtain Selank via personal import from Russian or Eastern European pharmacies. The Border Force and MHRA position on personal-import unlicensed medicines is restrictive in principle though enforcement intensity is variable; researchers should consult appropriate regulatory channels.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. Selank is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full Selank research context including mechanism, study citations, and references, see the main Selank research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.